Drugs / PBI-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05514353 | Dec 2021 → Jan 2023 | psoriasis | Pyramid Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04882631 | Apr → May 2021 | — | Pyramid Biosciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBI-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04882631 ↗ |
| Route | Topical | “A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.” NCT04882631 ↗ |